
Semaglutide
GLP-1 receptor agonist researched for appetite regulation and metabolic health.
About:
Semaglutide is a GLP-1 receptor agonist widely researched for appetite regulation and metabolic health. It mimics a naturally occurring incretin hormone, slowing gastric emptying and modulating hunger signalling.
What does this peptide do?
A large body of trial data, including the STEP program, has examined dosing strategies, tolerability, and long-term metabolic outcomes. Research continues into how gradual titration affects results and side-effect profiles.

Appetite regulation
Acts on appetite signalling as a GLP-1 receptor agonist.

Metabolic health
Trial data covers glucose control and long-term metabolic outcomes.
Evidence grade
AHighest evidence grade among the graded claims: A. Grades reflect study strength, not benefit.
What are the benefits and side effects of this peptide
What research says it may help with
- Weight loss and blood sugar effects are supported by multiple randomized trials and meta-analyses, including studies in people without diabetes.
Who should avoid it
- People who are pregnant or planning pregnancy
- People who are breastfeeding
- Children
- People with a personal or family history of medullary thyroid carcinoma or MEN2
- Personal or family history of medullary thyroid carcinoma
See the safety section. Absence of a flag is not evidence of safety.
A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.

How to store this peptide
Injectable formulations are studied with refrigerated storage before first use, with defined handling conditions once a pen or vial is in use, and are intended for single-patient use only.
Lyophilized storage
Refrigerate at 2–8 °C in the original carton. Do not freeze.
Reconstituted storage
Once in use, may be kept below 30 °C for the period stated on the product label.
Storage Handling
Protect from light. Do not use if it has been frozen.


